Letter to the editor re: contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100).

摘要

The study reported by Correas et al. was designed to determine the optimal dose of NCI00100 (Sonazoid?; Daiichi-Sankyo, Tokyo, Japan; GE Healthcare, Oslo, Norway) for detecting liver metastases in the late hepatospecific phase by a multi-centre approach [1]. Contrast-enhanced ultrasound (CEUS) produced a significant improvement compared to conventional ultrasound (US) in the sensitivity of lesion detection for each dose group (p<0.05) and for all doses combined (p<0.0001). The 0.12 dose group improvement was significantly higher than in the other groups (p<0.05). Compared with conventional US, the specificity of CEUS was greater in all dose groups combined (p>0.01) but only the 0.008 dose group reached significance on its own (p=0.045).